January 7, 2019 09:57 AM EST

Cheerful mid-stage depression drug data send Axsome stock flying

Natalie Grover

Reporter

On the same day Sage rolled out $SAGE tremendous oral drug data in postpartum depression, Axsome Therapeutics has announced that its lead experimental CNS …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cheerful mid-stage depression drug data send Axsome stock flying

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Cheer­ful mid-stage de­pres­sion drug da­ta send Ax­some stock fly­ing

Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Cheerful mid-stage depression drug data send Axsome stock flying